Hyperion Makes RAVICTI(TM) Available For Shipment To UCD Patients

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that RAVICTI™ (glycerol phenylbutyrate) Liquid is now available for shipment to patients. RAVICTI was approved by the U.S. Food and Drug Administration (FDA) on February 1, 2013, for use as a nitrogen-binding agent for the chronic management of adult and pediatric patients two years of age or older with urea cycle disorders (UCD), who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. The new drug is being distributed exclusively via select specialty pharmacies. To prescribe RAVICTI or for more information regarding the medication, reimbursement, and other patient support services, individuals may call 1-855-UCD-SUPT (1-855-823-7878) or visit www.ravicti.com .

RAVICTI Indications, Usage and Safety Information

RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients ≥ two years of age with UCD that cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, protein-free calorie supplements).

Limitations of Use:
  • RAVICTI is not indicated for the treatment of acute hyperammonemia (HA) in patients with UCD because more rapidly acting interventions are essential to reduce plasma ammonia levels.
  • The safety and efficacy of RAVICTI for the treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established.

RAVICTI is Contraindicated in Patients:
  • Less than two months of age. Children less than two months of age may have immature pancreatic exocrine function which could impair hydrolysis of RAVICTI, leading to impaired absorption of phenylbutyrate and HA.
  • With known hypersensitivity to phenylbutyrate. Signs of hypersensitivity include wheezing, shortness of breath, coughing, low blood pressure, flushing, nausea and rash.

The major metabolite of RAVICTI, PAA, is associated with neurotoxicity at levels ≥ 500 μg/mL. If symptoms of vomiting, nausea, headache, drowsiness, or confusion are present in the absence of high ammonia or other intercurrent illnesses, reduce the RAVICTI dosage.

If you liked this article you might like

Ireland’s Horizon Pharma Makes $3 Billion Hostile Bid for Depomed

Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks

Stock Markets Soar on Trifecta of Good News

Energy Sector Leads Stock Markets Higher as Rally Rolls On

Teva Buys Tourette Syndrome Drug Firm Auspex for $3.2 Billion